FDA readies for rivaroxaban stroke/AF review - TheHeart.Org PDF Print
TheHeart.Org
Adelphi, MD - The FDA has announced that its Cardiovascular and Renal Drugs Advisory Committee will meet September 8, 2011 to review the new drug application (NDA) for rivaroxaban (Xarelto, Bayer/Johnson & Johnson) for the prevention of stroke and

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.